Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Editas Medicine (EDIT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 966,718
  • Shares Outstanding, K 47,810
  • Annual Sales, $ 13,730 K
  • Annual Income, $ -120,320 K
  • 36-Month Beta 2.56
  • Price/Sales 31.16
  • Price/Cash Flow N/A
  • Price/Book 4.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.41
  • Number of Estimates 6
  • High Estimate -0.06
  • Low Estimate -0.73
  • Prior Year -0.84
  • Growth Rate Est. (year over year) +51.19%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.00 +6.42%
on 02/07/19
23.72 -14.76%
on 01/22/19
-5.92 (-22.65%)
since 01/18/19
3-Month
17.80 +13.60%
on 12/24/18
32.46 -37.71%
on 12/03/18
-6.93 (-25.52%)
since 11/19/18
52-Week
17.80 +13.60%
on 12/24/18
45.02 -55.09%
on 03/09/18
-13.60 (-40.21%)
since 02/16/18

Most Recent Stories

More News
Gamida Cell Announces Agreement with Editas Medicine to Evaluate Use of CRISPR Genome Editing Technology in NAM-NK Cells

Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced an agreement with Editas Medicine, Inc., a leading genome editing company, to evaluate...

GMDA : 14.00 (unch)
EDIT : 20.22 (+0.70%)
Editas Medicine (EDIT) Dips More Than Broader Markets: What You Should Know

Editas Medicine (EDIT) closed the most recent trading day at $19.86, moving -0.45% from the previous trading session.

EDIT : 20.22 (+0.70%)
Editas Medicine (EDIT) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Editas Medicine (EDIT) closed at $19.75, marking a +1.65% move from the previous day.

EDIT : 20.22 (+0.70%)
Editas Medicine Names David Scadden, M.D., to Board of Directors

Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that it has appointed David T. Scadden, M.D., to its Board of Directors, effective immediately.

EDIT : 20.22 (+0.70%)
Editas Medicine (EDIT) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Editas Medicine (EDIT) closed at $21.60, marking a -0.6% move from the previous day.

EDIT : 20.22 (+0.70%)
Editas Medicine (EDIT) Gains But Lags Market: What You Should Know

In the latest trading session, Editas Medicine (EDIT) closed at $21.46, marking a +0.61% move from the previous day.

EDIT : 20.22 (+0.70%)
Editas Medicine Announces Chief Executive Officer Transition

Katrine Bosley to Step Down as President and CEO

EDIT : 20.22 (+0.70%)
Editas Medicine Announces Publication in Nature Medicine of Data Supporting the Development of EDIT-101 to Treat Leber Congenital Amaurosis 10 (LCA10)

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the journal Nature Medicine published the comprehensive, pre-clinical data demonstrating the pharmacology and specificity...

EDIT : 20.22 (+0.70%)
Editas Medicine (EDIT) Stock Sinks As Market Gains: What You Should Know

Editas Medicine (EDIT) closed at $26.03 in the latest trading session, marking a -0.69% move from the prior day.

EDIT : 20.22 (+0.70%)
Editas Medicine (EDIT) Dips More Than Broader Markets: What You Should Know

Editas Medicine (EDIT) closed at $26.20 in the latest trading session, marking a -0.8% move from the prior day.

EDIT : 20.22 (+0.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade EDIT with:

Business Summary

Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 20.66
1st Resistance Point 20.44
Last Price 20.22
1st Support Level 20.00
2nd Support Level 19.78

See More

52-Week High 45.02
Fibonacci 61.8% 34.62
Fibonacci 50% 31.41
Fibonacci 38.2% 28.20
Last Price 20.22
52-Week Low 17.80

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar